Lethal Brain Cancer – Glioblastoma – Is a Breakthrough at Hand? John sits down with Dr. Fahar Merchant of Medicenna Therapeutics Corporation.
Dr. Merchant is a 25-year biotech veteran, a serial entrepreneur and co-founder of Medicenna. Previously he was President and CEO of Protox Therapeutics (TSX.V and TSX; now Sophiris Bio, Nasdaq) where he established a late clinical stage urology company. At Protox he raised more than $70M through multiple PIPEs, including a $35M investment by Warburg Pincus. In 1992 he co-founded IntelliGene Expressions, Inc., a biologics CDMO, and built it into one of the fastest growing companies in Canada. In 2000, by strategic in-licensing, he co-founded Avicenna Medica, Inc., a clinical stage oncology company that was sold a year later to KS Biomedix (LSE) for $90M. Fahar was CTO and Director of KS Biomedix until its acquisition by Xenova (Nasdaq and LSE; now Celtic Pharma). Fahar has closed several transactions valued at more than $300M. He has a PhD in Biochemical Engineering from Western University.
Share this via:
- Click to email this to a friend (Opens in new window)
- Click to share on WhatsApp (Opens in new window)
- Click to share on Twitter (Opens in new window)
- Click to share on Facebook (Opens in new window)
- Click to share on LinkedIn (Opens in new window)
- Click to share on Pinterest (Opens in new window)
- Click to share on Telegram (Opens in new window)
- More